---

$1.49

-0.0500 ( -3.25% ) 32.6K

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell-based immunotherapies for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company's lead program, INB-100, is focused on acute myeloid leukemia evaluating haplo-matched allogeneic γδ T cells given to patients following a hematopoietic stem cell transplant. The company is also evaluating autologous DeltEx DRI γδ T cells, in combination with standard of care, for glioblastoma, and advancing novel γδ T cell engagers for potential oncology and autoimmune indications.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2024-06-14	Sale	-33650.00	Brandt Peter C.
2024-06-14	Sale	-33650.00	Roemer Alan S.
2024-02-08	Sale	-169000.00	Lamb Lawrence
2024-02-08	Sale	-189000.00	McCall Patrick
2024-02-08	Sale	-176000.00	Goswami Trishna
2024-02-08	Sale	-502000.00	Ho William Tai-Wei
2024-02-08	Sale	-12500.00	Epperly Corinne
2024-02-08	Sale	-186000.00	Rochlin Kate
2023-12-15	Sale	-2049.00	Graff Jeremy R.
2023-12-15	Sale	-81967.00	Epperly Corinne